AUS
NZ
UK
CA
USA
IND
Highlights
- ResMed (ASX:RMD) has retreated despite continued operational momentum across its sleep and respiratory care business.
- The healthcare company is trading below valuation levels typically seen among global medical technology peers.
- Temple & Webster (ASX:TPW) also features among Australian companies attracting attention as a value-oriented growth story.
ResMed Limited (ASX:RMD), the Australian-founded global medical technology company specialising in sleep apnoea, respiratory care and digital health solutions, has re-entered the conversation among value-focused Australian equities after recent weakness in its share price contrasted with continued operational progress.
While healthcare stocks have generally lagged sectors such as financials and resources during recent market rotation, ResMed's underlying business continues to report expanding revenue, improving profitability and growing software adoption across international markets. The disconnect between operational performance and market valuation has prompted renewed interest in the company alongside other Australian businesses trading below estimates of their longer-term earnings potential.
Temple & Webster Group Ltd (ASX:TPW), Australia's online furniture and homewares retailer, also presents a contrasting example of a business where forecast growth expectations continue to exceed recent share price performance.
ResMed's operating performance remains resilient
Despite softer trading in its share price, ResMed continues benefiting from long-term demand for sleep-disorder diagnosis and respiratory care products.
The company maintains leadership across several healthcare segments, including:
- Continuous positive airway pressure devices.
- Sleep apnoea masks.
- Cloud-connected patient monitoring platforms.
- Respiratory therapy software.
These businesses continue supporting recurring revenue through ongoing equipment replacement, accessories and digital healthcare services.
Valuation gap widens against global peers
Market attention has increasingly focused on the valuation difference between ResMed and comparable international medical device companies.
While many global healthcare technology businesses continue attracting premium earnings multiples, ResMed has traded at comparatively lower valuation levels despite maintaining steady operational execution.
This divergence has encouraged renewed discussion around whether broader healthcare sector sentiment has become disconnected from company-specific fundamentals.
Software platform strengthens recurring revenue
One of ResMed's longer-term strategic advantages remains its expanding digital health ecosystem.
Beyond manufacturing medical devices, the company continues increasing revenue generated through connected healthcare platforms that assist clinicians in monitoring patient compliance and treatment outcomes.
The continued expansion of these software services provides an increasingly diversified earnings base beyond hardware sales alone.
International expansion supports growth
ResMed also continues expanding across international healthcare markets where sleep disorders remain significantly underdiagnosed.
Growing awareness of sleep apnoea, combined with ageing populations and improved diagnostic capabilities, continues creating opportunities for product adoption across North America, Europe and Asia.
These structural healthcare trends remain supportive of longer-term demand irrespective of shorter-term market volatility.
Healthcare sector rotation weighs on sentiment
The recent weakness in ResMed's share price also reflects broader market positioning.
During recent months, Australian equity markets have favoured sectors benefiting from stronger commodity prices and financial sector resilience, while healthcare companies have generally experienced more subdued investor interest.
This broader sector rotation has affected several established healthcare businesses despite stable operating performance.
Acquisition integration remains under watch
Recent acquisitions have also influenced market sentiment.
Although management expects strategic acquisitions to strengthen the company's long-term product portfolio, integration costs can temporarily affect reported earnings during the initial implementation period.
Management has continued highlighting the strategic importance of expanding beyond traditional sleep therapy products into adjacent respiratory care opportunities.
Temple & Webster presents a different value story
Temple & Webster represents a different segment of the Australian market but shares a similar valuation discussion.
The online retailer continues benefiting from:
- Growth in active customers.
- Expanding private-label offerings.
- Improvements in logistics capabilities.
- Higher repeat purchasing activity.
Despite ongoing operational development, the company's valuation has moderated alongside broader weakness across consumer discretionary businesses.
The combination of continued revenue growth and more conservative market pricing has placed Temple & Webster on several value-oriented investment screens.
Improving margins support ResMed
ResMed has continued reporting favourable operating trends supported by:
- Higher device sales.
- Strong accessories demand.
- Growth in digital healthcare services.
- Continued gross margin expansion.
The company's increasingly diversified business model reduces reliance on any single product category while strengthening recurring cash flow generation.
Value themes re-emerge across the market
Recent market conditions have seen greater attention directed toward companies where operational fundamentals remain stable despite weaker share price performance.
For businesses such as ResMed and Temple & Webster, the current valuation discussion centres on whether recent market weakness fully reflects long-term earnings potential or simply broader sector rotation.
As reporting season approaches, upcoming financial updates are expected to provide additional evidence regarding earnings trends, customer demand and management outlook.
ResMed continues demonstrating operational resilience through expanding digital healthcare services, global market growth and improving profitability, even as its valuation has moderated relative to international medical technology peers. Together with Temple & Webster, the company illustrates how broader market rotation has created renewed discussion around value opportunities among businesses with established earnings profiles and long-term growth strategies.
